Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) An altered antibody or functional fragment thereof which binds to and neutralises MAG and which comprises one or more CDR's selected from CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3.~~of the following CDR's.~~

~~***Light chain CDRs***~~

~~***CDR***~~	~~***According to Kabat***~~
~~L1~~	~~KSSHSVLYSSNQKNYLA~~
~~L2~~	~~WASTRES~~
~~L3~~	~~HQYLSSLT~~

~~***Heavy chain CDRs***~~

~~***CDR***~~	~~***According to Kabat***~~
~~H1~~	~~NYGMN~~
~~H2~~	~~WINTYTGEPTYADDFTG~~
~~H3~~	~~NPINYYGINYEGYVMDY~~

2. (Currently Amended) An altered antibody or functional fragment thereof which comprises a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 ~~and/or~~or a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3.

3. (Currently Amended) An altered anti-Mag antibody or functional fragment thereof which comprises:

a heavy chain variable domain ~~(V_H)~~ which comprises~~in sequence~~ hypervariable regions CDRH1, CDRH2 and CDRH3

~~and /or~~or

a light chain variable domain ~~(V_L)~~ which comprises ~~in sequence~~ hypervariable regions CDRL1, CDRL2 and CDRL3.

4. (Original) An antibody of claim 3 which is monoclonal.

5. (Original) An antibody of claim 4 which is humanised.

6. (Currently Amended) An antibody or functional fragment thereof ~~that~~ according to claim 5, further comprising ~~which comprises~~ a heavy chain variable region comprising one of the following amino acid sequences

QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG
WINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCAR
NPINYYGINYEGYVMDYWGQGTLVTVSS (SEQ ID No 13)

QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG
WINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCAR
NPINYYGINYEGYVMDYWGQGTLVTVSS (Sequence ID No 14)

QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG
WINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTATYFCAR
NPINYYGINYEGYVMDYWGQGTLVTVSS (sequence ID No 15)

~~QVQLVQSGSELKKPGASVKVSCKASGYTFT**NYGMN**WVRQAPGQGLEWMG~~
~~**WINTYTGEPTYADDFTG**RFVFSLDTSVSTAYLQISSLKAEDTAVYYCAR~~
~~**NPINYYGINYEGYVMDY**WGQGTLVTVSS (SEQ ID No 13).~~

~~QVQLVQSGSELKKPGASVKVSCKASGYTFT**NYGMN**WVRQAPGQGLEWMG~~
~~**WINTYTGEPTYADDFTG**RFVFSLDTSVSTAYLQISSLKAEDTAVY**F**CAR~~
~~**NPINYYGINYEGYVMDY**WGQGTLVTVSS (Sequence ID No 14)~~

~~QVQLVQSGSELKKPGASVKVSCKASGYTFT**NYGMN**WVRQAPGQGLEWMG~~
~~**WINTYTGEPTYADDFTG**RFVFSLDTSVSTAYLQISSLKAEDTA**T**Y**F**CAR~~
~~**NPINYYGINYEGYVMDY**WGQGTLVTVSS (sequence ID No 15)~~

7. (Currently Amended) An antibody or functional fragment thereof according to claim 6 further comprising a light chain variable region comprising one of the following amino acid sequences ~~amino acid Sequence ID No 16, 17, 18 or 19:~~

DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQP
PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYL
SSLTFGQGTKLEIKRTV (SEQ ID No 16)

DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQP
PKLLIYWASTRESGVPDRFSGSGSGTDFTLTIINLQAEDVAVYYCHQYL
SSLTFGQGTKLEIKRTV (SEQ ID No 17)

DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQP
PKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLHTEDVAVYYCHQYL
SSLTFGQGTKLEIKRTV (SEQ ID No 18)

DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQP
PKLLIYWASTRESGVPDRFSGSGSGTDFTLTIINLHTEDVAVYYCHQYL
SSLTFGQGTKLEIKRTV (SEQ ID No 19)

~~DIVMTQSPDSLAVSLGERATINC**KSSHSVLYSSNQKNYLA**WYQQKPGQP
PKLLIY**WASTRES**GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC**HQYL
SSLT**FGQGTKLEIKRTV (SEQ ID No 16)~~

~~DIVMTQSPDSLAVSLGERATINC**KSSHSVLYSSNQKNYLA**WYQQKPGQP
PKLLIY**WASTRES**GVPDRFSGSGSGTDFTLTI**IN**LQAEDVAVYYC**HQYL
SSLT**FGQGTKLEIKRTV (SEQ ID No 12)~~

~~DIVMTQSPDSLAVSLGERATINC**KSSHSVLYSSNQKNYLA**WYQQKPGQP
PKLLIY**WASTRES**GVPDRFSGSGSGTDFTLTISSL**HT**EDVAVYYC**HQYL
SSLT**FGQGTKLEIKRTV (SEQ ID No 18)~~

~~DIVMTQSPDSLAVSLGERATINC**KSSHSVLYSSNQKNYLA**WYQQKPGQP
PKLLIY**WASTRES**GVPDRFSGSGSGTDFTLTI**IN**L**HT**EDVAVYYC**HQYL
SSLT**FGQGTKLEIKRTV (SEQ ID No 19)~~

Claims 8- 16 (Cancelled)

17. (Currently Amended) A pharmaceutical composition comprising an altered anti-MAG antibody or functional fragment thereof according to ~~claims 1-8~~ claim 3 together with a pharmaceutically acceptable diluent or carrier.

18. (Currently Amended) A method of treatment or prophylaxis of stroke and other neurological diseases/disorders in a human which comprises administering to said

human in need thereof an effective amount of an anti-MAG antibody, according to ~~claims 1-8~~ claim 3 including altered antibodies or a functional fragment thereof.

19. (Currently Amended) The use of an anti-MAG antibody according to claims ~~1-8~~ claim 3, including altered antibodies or a functional fragment thereof in the preparation of a medicament for treatment or prophylaxis of stroke and other neurological diseases/disorders.

20. (Currently Amended) A method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease/disorder which comprises administering to said human in need thereof an effective amount of an anti-MAG antibody according to ~~claims 1-6~~ claim 3, including altered antibodies or a functional fragment thereof.

21. (Currently Amended) The use of an anti-MAG antibody according to ~~claims 1-8~~ claim 3, including altered antibodies or a functional fragment thereof in the preparation of a medicament for inhibiting neurodegeneration ~~and/or~~or promoting functional recovery in a human patient afflicted with, or at risk of developing, a stroke and other neurological disease/disorder.

22. (Original) A method of treating or prophylaxis of stroke or other neurological disease/disorder in a human comprising the step of parenteral administration of a therapeutically effective amount of an anti-MAG antibody to said human.

23. (Original) The method of claim 22 wherein the anti-MAG antibody is administered intravenously.

24. (Currently Amended) The method of claim 18 ~~, 20 or 24~~ wherein the other neurological disease/disorder is selected from the group consisting of; traumatic brain injury, spinal cord, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease and multiple sclerosis.

25. (Currently Amended) A method of promoting axonal sprouting comprising the step of contacting a human axon with an anti-MAG antibody of ~~claims 1 to 8~~ claim 3.

26. (Original) The method of claim 25 wherein the method is *in vitro*.